Currently, risk stratification and prognosis stratification of primary central nervous system lymphoma (PCNSL) is predominantly based on the Memorial Sloan-Kettering Cancer Center (MSKCC) model, but the prognostic value is controversial. Recently, the systemic immune-inflammation index (SII) has been considered as an important prognostic factor in PCNSL. 174 newly diagnosed PCNSL patients treated with methotrexate-based combination immunochemotherapy were analyzed in two retrospective discovery cohorts (n=128) and one prospective validation cohort (n=46) to determine whether the SII-MSKCC model could better predict the clinical outcomes. Generalized additive model, Kaplan–Meier curve, and Cox analysis were performed. The scores of SII-MSKCC model were: 890>SII>450, score=0; SII<450, score=1; SII>890, score=2; Age≦50, score=0; age >50 + KPS≧70, score=1; age >50 + KPS≦70, score=2. Here, we report the results of discovery cohort that SII-MSKCC model provided higher prognostic performance compared with the MSKCC model. We further validate the prognosis value of the SII-MSKCC model with an external dataset from an independent prospective cohort, which confirmed its robustness. In multivariable analysis, the SII-MSKCC model remained significantly independently associated with clinical outcomes. Thus, SII-MSKCC model could be used across centers to better predict prognosis in PCNSL.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.